Organicell Regenerative Medicine
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Organicell Regenerative Medicine generated cash of -$2,197,275, which is more than the previous year. Cash used in financing activities reached the amount of -$415,186 last year. Net change in cash is therefore -$1,996,895.
Cash Flow
| 2014 | -64.73K | 0 | 46.81K |
|---|---|---|---|
| 2015 | -384.79K | -7.90K | 491.74K |
| 2016 | -548.18K | -20.13K | 556.97K |
| 2017 | -881.52K | -45.13K | 940K |
| 2018 | -511.99K | 95.45K | 420K |
| 2019 | -565.45K | -32.73K | 687.73K |
| 2020 | -1.81M | -138.69K | 2.40M |
| 2021 | -2.60M | -496.01K | 2.62M |
| 2022 | -3.16M | -824.74K | 7.63M |
| 2023 | -2.19M | 615.56K | -415.18K |
OCEL Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 3.75M | 108.57K | 590.79K | 132.55K | 43.01K | 39.56K | 26.22K | 37.56K | 244 | 15.94K |
Operating activities | ||||||||||
Net income | -6.98M | -8.89M | -12.75M | -12.58M | -1.73M | -3.43M | -9.11M | -1.05M | -762.88K | -65.81K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 486.35K | 332.50K | 52.70K | 36.77K | 14.79K | 7.83K | 19.31K | 345 | 86 | 0 |
Stock-based compensation expense | 3.20M | 3.91M | 8.65M | 9.91M | 727.41K | 4.02M | 5.82M | 0 | 268K | 0 |
| Deferred income tax benefit | 3.20M | 3.91M | 8.65M | 9.91M | 727.41K | 4.02M | 5.82M | 0 | 268K | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 36.89K | 17.14K | -74.76K | -3.69K | 11.35K | 4.69K | -119.08K | 18.25K | 80.03K | 0 |
Inventories | -61.67K | -51.13K | -88.01K | -68.84K | -77.96K | 60.31K | -109.61K | -9.94K | -1.60K | 5.83K |
Accounts payable | 233.43K | 1.03M | 1.22M | 218.75K | 75.58K | 64.78K | 343.35K | 516.60K | 9.35K | -19.21K |
Cash generated by operating activities | -2.19M | -3.16M | -2.60M | -1.81M | -565.45K | -511.99K | -881.52K | -548.18K | -384.79K | -64.73K |
Investing activities | ||||||||||
Purchases Of Investments | -100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -25.39K | -824.74K | -496.01K | -138.69K | -32.73K | -4.56K | -45.13K | -26.31K | -7.90K | 0 |
Acquisitions Net | 740.95K | 0 | 0 | 0 | 0 | 100.02K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 615.56K | -824.74K | -496.01K | -138.69K | -32.73K | 95.45K | -45.13K | -20.13K | -7.90K | 0 |
Financing activities | ||||||||||
Common Stock Issued | 100K | 7.27M | 2.70M | 2.19M | 459.5K | 100K | 505K | 457.27K | 496.2K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -500K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -84.40K | -185.88K | 0 | -320K | 0 | -300 | 0 | 0 |
Cash used in financing activities | -415.18K | 7.63M | 2.62M | 2.40M | 687.73K | 420K | 940K | 556.97K | 491.74K | 46.81K |
Net Change In Cash | -1.99M | 3.64M | -482.22K | 458.24K | 89.54K | 3.45K | 13.33K | -11.34K | 99.05K | -15.70K |
Cash at end of period | 1.75M | 3.75M | 108.57K | 590.79K | 132.55K | 43.01K | 39.56K | 26.22K | 99.29K | 244 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |